{"id":8971,"date":"2010-07-12T11:34:27","date_gmt":"2010-07-12T15:34:27","guid":{"rendered":"http:\/\/asweetlife.org\/?p=8971"},"modified":"2015-12-29T08:57:18","modified_gmt":"2015-12-29T13:57:18","slug":"jdrf-grants-407000-to-evaluate-use-of-biodels-viajectr-in-treatment-of-diabetes","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=8971","title":{"rendered":"JDRF Grants $407,000 to Evaluate Use of Biodel&#8217;s VIAject(R) in Treatment of Diabetes"},"content":{"rendered":"<p style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/07\/biodel_logo.png\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-full wp-image-8976 lazyload\" style=\"margin: 4px;\" title=\"biodel_logo\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/07\/biodel_logo.png\" alt=\"\" width=\"140\" height=\"60\" \/><\/a>Biodel Inc. <a href=\"http:\/\/investor.biodel.com\/releasedetail.cfm?ReleaseID=486780\" target=\"_blank\">announced<\/a> the award of two research grants by the Juvenile Diabetes Research Foundation (JDRF) to Stanford University and Oregon Health &amp; Science University (OHSU) to evaluate the use of <a href=\"https:\/\/asweetlife.org\/a-sweet-life-staff\/featured\/better-faster-stronger-creating-ultra-rapid-insulin\/8843\/\">VIAject(R) (ultra-rapid-acting injectable human insulin)<\/a> in the treatment of diabetes. The first grant will support clinical testing under the direction of Bruce Buckingham, M.D., professor of pediatrics at Stanford University School of Medicine, to compare the effects of VIAject(R) and Humalog(R) (insulin lispro) on postprandial glycemia when used with insulin pumps. The second grant will support clinical testing at OHSU under the direction of W. Kenneth Ward, M.D., associate professor at OHSU, to evaluate the use of VIAject(R) to improve closed-loop, (artificial pancreas) glycemic control in patients with Type 1 diabetes. Biodel will supply VIAject(R) to these institutions which will receive a total of approximately $407,000 from JDRF to fund the two research projects over the next year.<br \/> VIAject(R) is Biodel&#8217;s proprietary ultra-rapid-acting formulation of recombinant human insulin that is designed to be absorbed into the blood faster than currently marketed rapid-acting insulin analogs. It has been tested in more than 875 patients who participated in Phase 1, 2 and 3 clinical trials of the drug in the United States, Germany and India. Biodel has submitted an application to the U.S. Food and Drug Administration for clearance to market VIAject(R) for the treatment of diabetes.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biodel Inc. announced the award of two research grants by the Juvenile Diabetes Research Foundation (JDRF) to Stanford University and Oregon Health &#038; Science University (OHSU) to evaluate the use of VIAject(R) (ultra-rapid-acting injectable human insulin) in the treatment of diabetes. The first grant will support clinical testing under the direction&#8230;<\/p>\n","protected":false},"author":131,"featured_media":8976,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1441],"tags":[622],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>JDRF Grants $407,000 to Evaluate Use of Biodel&#039;s VIAject(R) in Treatment of Diabetes<\/title>\n<meta name=\"description\" content=\"JDRF Grants $407,000 to Stanford University and Oregon Health &amp; Science University (OHSU) to evaluate the use of VIAject(R), an ultra-rapid-acting injectable insulin in the treatment of diabetes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=8971\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=8971\",\"url\":\"https:\/\/asweetlife.org\/?p=8971\",\"name\":\"JDRF Grants $407,000 to Evaluate Use of Biodel's VIAject(R) in Treatment of Diabetes\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=8971#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=8971#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/07\/biodel_logo.png\",\"datePublished\":\"2010-07-12T15:34:27+00:00\",\"dateModified\":\"2015-12-29T13:57:18+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"JDRF Grants $407,000 to Stanford University and Oregon Health & Science University (OHSU) to evaluate the use of VIAject(R), an ultra-rapid-acting injectable insulin in the treatment of diabetes.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=8971#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=8971\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=8971#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/07\/biodel_logo.png\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/07\/biodel_logo.png\",\"width\":175,\"height\":75,\"caption\":\"biodel logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=8971#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"JDRF Grants $407,000 to Evaluate Use of Biodel&#8217;s VIAject(R) in Treatment of Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"JDRF Grants $407,000 to Evaluate Use of Biodel's VIAject(R) in Treatment of Diabetes","description":"JDRF Grants $407,000 to Stanford University and Oregon Health & Science University (OHSU) to evaluate the use of VIAject(R), an ultra-rapid-acting injectable insulin in the treatment of diabetes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=8971","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=8971","url":"https:\/\/asweetlife.org\/?p=8971","name":"JDRF Grants $407,000 to Evaluate Use of Biodel's VIAject(R) in Treatment of Diabetes","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=8971#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=8971#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/07\/biodel_logo.png","datePublished":"2010-07-12T15:34:27+00:00","dateModified":"2015-12-29T13:57:18+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"JDRF Grants $407,000 to Stanford University and Oregon Health & Science University (OHSU) to evaluate the use of VIAject(R), an ultra-rapid-acting injectable insulin in the treatment of diabetes.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=8971#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=8971"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=8971#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/07\/biodel_logo.png","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/07\/biodel_logo.png","width":175,"height":75,"caption":"biodel logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=8971#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"JDRF Grants $407,000 to Evaluate Use of Biodel&#8217;s VIAject(R) in Treatment of Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/8971"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8971"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/8971\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/8976"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}